![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
Active Filter(s):
Details:
BeiGene provided a program update on their ongoing Phase 1b/2 study evaluating the combination of BeiGene’s investigational RAF dimer inhibitor, lifirafenib, with SpringWorks’ MEK inhibitor, mirdametinib, in solid tumors harboring mutations in the MAPK pathway.
Lead Product(s): Lifirafenib,Mirdametinib
Therapeutic Area: Oncology Product Name: BGB-283
Highest Development Status: Phase I/ Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: SpringWorks Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2020